Table 3.

Number of newly diagnosed depressive and anxiety disorders between patients with pSS and control subjects, stratified by followup duration.

FollowupPatients with pSSPatients without pSSRR (95% CI)
Duration, YrNo. Depressive DisordersPer 1000 Person-YrsNo. Depressive DisordersPer 1000 Person-Yrs
Overall856.391743.231.98 (1.51–2.58)*
0–1124.48222.052.19 (0.99–4.61)
1–5555.291022.422.18 (1.54–3.05)*
≥ 5181.35500.931.46 (0.80–2.54)
No. Anxiety DisordersPer 1000 Person-YrsNo. Anxiety DisordersPer 1000 Person-Yrs
Overall675.001452.691.86 (1.37–2.50)*
0–1103.73161.492.50 (1.02–5.88)*
1–5444.21922.191.93 (1.31–2.79)*
≥ 5130.97370.691.41 (0.69–2.72)
No. Sleep DisordersPer 1000 Person-YrsNo. Sleep DisordersPer 1000 Person-Yrs
Overall554.101172.161.89 (1.35–2.63)*
0–182.99161.492.00 (0.74–4.96)
1–5343.25671.592.04 (1.31–3.13)*
≥ 5130.97340.631.54 (0.75–3.00)
  • * Statistical significance. pSS: primary Sjögren syndrome; RR: risk ratio.